CXCR3 and neoplasm: High CXCR3 expression on activated T cells has not only been shown to be a robust predictor for the success of cell-based immunotherapies [19] but may also be upregulated in tumor-resident T cells due to immune checkpoint inhibition-induced T cell activation [15, 19].